[DEF 14A] GeneDx Holdings Corp. Definitive Proxy Statement
GeneDx Holdings Corp. has issued its definitive proxy statement (DEF 14A) for its 2026 virtual annual meeting on June 18, 2026. Stockholders will vote on the election of one Class II director, the ratification of Ernst & Young LLP as auditor, non-binding advisory approval of executive compensation, and the frequency of future say-on-pay votes. The proxy statement details the company's strong 2025 financial performance, including significant revenue growth and adjusted net income, and outlines the executive compensation philosophy which emphasizes a pay-for-performance culture through a mix of base salary, annual cash incentives, and long-term equity incentives, including performance-based restricted stock units (PRSUs).
APR 29·Stock Titan→
Insider sells Class A stock at WGS (NASDAQ: WGS) — multiple lots reported
An insider at WGS (NASDAQ: WGS) has filed a Form 144, indicating proposed dispositions of Class A Common Stock. The filing details multiple sales reported in early 2026, totaling over 22,000 shares across several dates, originating from restricted stock units acquired between 2022 and 2023. Morgan Stanley Smith Barney is listed as the broker and NASDAQ as the market for these transactions.
APR 29·Stock Titan→
WGS (NASDAQ: WGS) affiliate sales reported in Form 144; multiple 2026 trades listed
A recent Form 144 filing for GeneDx Holdings Corp. (NASDAQ: WGS) indicates multiple proposed sales of Class A common stock by affiliate Katherine Stueland during 2026. The filing details several sales derived from Restricted Stock Units, along with the individual quantities sold and Stueland's remaining holdings after each transaction. These are routine disclosures of equity compensation dispositions rather than corporate actions.
